VLTC has pushed this up for no reason. Big wigs bought sub 1's so are in the money. Which is the better short term bet, short anything above Fridays close or buy 1.20 - 1.40 area? Monday will close red, but may get a small pop to the 1.80 area before going back down.
Interest in this company is Rising. Could Double in a Flash
Buyout for one, could cause a double or more very quickly.
One thing is sure, Carl Icahn and his three Amigos did not acquire shares at north of $3.00 a share, install his own people, just to have a stock worth $1.40....Does not make sense and is Not what Billionaires do.
What does make sense, they bought in and installed own people, because they want to make money, a lot of money. That is what Billionaires do. Icahn and company that, times X10
When the time comes, could be tomorrow, could be a year from now. ENZN Shares Will Cost A Lot More then Now, a lot more! Carl and company will make money, we will make money, and again, Carl Icahn increases shareholder value...and his pockets too. Want to ride the train?
The fact that the stock has so much interest, noted by recent huge volume and Large following on many stock boards. Not just her on Yahoo.
I do believe the volume and interest, is an indication that something is in the works.
Where there is smoke, there usually is a fire or one about to flare up.
Have to ask yourself, how long can you WAIT to Double or more your money. A lot more if you accumulate as it rises. A week? A Month? Year? In a year a person could accumulate an insane amount of shares!!
Again, I think the volume is telling US, something is going to happen, and a lot Sooner then later.
Doubling, Tripling, etc,,money is one of the greatest feelings.
Buy Low, Sell to the Next Guy for A lot More!
I'll take $5.00 a share...or will someday.
What do you think?
Sentiment: Strong Buy
So I've read a lot lately how this stock is so awful because of it's charts, how the sales are disappearing, and how the dividends are shrinking. I'll explain why this is still a no-brainer BUY.
Through mid-2013, they sold off assets in excess of $88M, and turned around and handed that cash to shareholders in the form of a $2.00 div (Dec '12). Then they used the royalty money in the account (roughly $77M to begin 2013) and paid another 1.60 div only six months later (June '13).
In 2013, they began with $77M in cash, and had significant expenses. They net profited $18.2M and paid $2.05 in divs that year. The company overhauled their entire force- They eliminated R&D, marketing, etc and also cut all of the compensated employees except for 1, and the paid board members. They used that year to pay off the severance, take their hits, and get straightened out.
In 2014, they began with $6.5M in cash (after paying out 4.05/share in divs over previous 14 months).
Under the new structure, they profited $28M in 2014 (instead of $18M) EVEN THOUGHT THEIR SALES WERE DECLINING. Not knowing what effects the product expirations would have on 2015 sales, they issued a 'supplemental" div of $0.10 back in January.
So start after the $0.10 div was issued (which went on 2014 financials btw)... they started 2015 with $35M in cash. They project to make between $.09-0.13 EPS on Friday. Even if it's .09, thats $4M in net profit for Q1. Meaning the company will have $39M to hand out, and can safely project another $12M for the rest of the year. Which puts them at $51M in cash. And that's being extremely conservative. Most would agree they willdo around 0.11 EPS, putting them at $41M in cash, projecting $55M after Q1.
My point is, regardless of what type of Q1 they have, the div will come soon. And you can expect them to clear the account. So even if they don't start handing out the Q1 profit, they still will dispense that $35M soon, which is an $0.80 div by itself. -Z
Though the stats may be too much to chew, this is a steal under $2. Icahn and Simmons being in the name as a steady source of revenue (dividends, royalties) with barely any costs. Huge buyout potential obvious?
I'll answer my own question,,, Rev from BEL-0222 could potentially exceed 60 Million annually,
JUST FOR PEG-SN38 existing agreement with Hisun, We also get a piece of any new agreements
FROM 8K: ASSET SALE TO BELROSE
"The aggregate upfront consideration for the assets is $800,000, $700,000 of which the Company received at closing and $100,000 of which was placed into escrow and is to be released to the Company if the Company consummates the sale of its right, title and interest in the LNA Technology platform and related assets to Belrose. The Agreement also entitles the Company to receive from Belrose additional potential payments, including a share of net revenues that may be received from Hisun related to PEG-SN38 rights in China as well as a share of other potential partnering revenues. The achievement of any of these potential payments is uncertain. "
PEG-SN38 is very promising and in Phase III,,,
I have been following ENZN close for the last 3 months and am very familiar with its numbers, charting and sentiment. According to my data, we will see a good size spiked today with minor fluctuation with a strong close on the low end of the spectrum of 1.80.
Sentiment: Strong Buy
Here are a list of facts that are indisputable, and should be considered:
1. Although, Enzon has terminated its R&D, they currently receive Royalty Revenue in the amount of $31.2 Million
2. In December 21, 2010, our Board of Directors had authorized a share repurchase program under which we are authorized to repurchase up to $200.0 million of our outstanding common stock. Since the inception of this share repurchase program, the cumulative number of shares repurchased and retired through December 31, 2014 amounts to 16,174,578 shares at a total cost of $153.4 million, or an average cost per share of approximately $9.48.
3. The net effect of the foregoing was an increase of cash and cash equivalents of $28.1 million, from $6.5 million at December 31, 2013 to $34.6 million at December 31, 2014.
4. From the amended 10-K/A (April 24, 2015):
Group comprised of Carl C. Icahn and affiliated entities: 5,904,863 (13.36%)
BlackRock, Inc.: 3,861,315 (8.74%)
Group comprised of Stonepine Capital, L.P., Stonepine Capital Management, LLC, Jon M. Plexico and Timothy P. Lynch: 3,401,783 (7.70%)
5. ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON TUESDAY, JUNE 30, 2015. Take a good look at the BIO of the Chairman of the Board Nominee: (Jonathan Christodoro has served as a Managing Director of Icahn Capital LP, the entity through which Carl C. Icahn manages investment funds)
6. I do believe that Enzon could very well be a buyout target, as its assets and established publicly traded corporate structure is a built in vehicle to acquire other-like bio-pharma entities. Icahn is notorious for slowly building a position to steer a company in a desired direction, with the ultimate to acquire that company – I do believe that it’s not just a coincidence that the Board of Director nominee (Jonathan Christodoro) was a Managing Director at Icahn Capital LP!
Sentiment: Strong Buy
Yup, nothing but royalties flowing in till 2019. Cash back to shareholders. Can't beat that with a stick
What you fail to realize is, us the royalties will subside come 2019, but this company (with the NOLs they hold) has tax benefits that go to 2030s. They carry over all the benefits that they have yet to use. Along with the free cash this company brings in... Its no wonder some big name institutional investors hold big stakes and adding.
Hua Bai, CEO and Chairman of Hisun, added, "Enzon's PEGylation technology is utilized in approved products generating a combined total of over $7 billion in annual sales, making them the partner of choice for validated PEGylation technology. In addition to obtaining rights to PEG-SN38, this partnership provides Hisun access to innovative technology and development capabilities that will allow us to deliver novel therapeutics to the rapidly growing pharmaceutical market in China."
Just do a search about this. This could be huge revenues.
according to the Wall Street Journal report this morning. This is a big strike against Gilead's Hep C treatment. Merck bought out Idenix last summer for $3.85 billion. It's going to be an exciting coming week for the Longs.